242 related articles for article (PubMed ID: 24962200)
1. Advances in genetic and epigenetic analyses of gliomas: a neuropathological perspective.
Tsankova NM; Canoll P
J Neurooncol; 2014 Sep; 119(3):481-90. PubMed ID: 24962200
[TBL] [Abstract][Full Text] [Related]
2. Tailored therapy in diffuse gliomas: using molecular classifiers to optimize clinical management.
Taylor JW; Chi AS; Cahill DP
Oncology (Williston Park); 2013 Jun; 27(6):504-14. PubMed ID: 23909061
[TBL] [Abstract][Full Text] [Related]
3. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients.
Draaisma K; Wijnenga MM; Weenink B; Gao Y; Smid M; Robe P; van den Bent MJ; French PJ
Acta Neuropathol Commun; 2015 Dec; 3():88. PubMed ID: 26699864
[TBL] [Abstract][Full Text] [Related]
4. Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future.
Chen R; Cohen AL; Colman H
Curr Treat Options Oncol; 2016 Aug; 17(8):42. PubMed ID: 27334978
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic dysregulation in glioma.
Kondo Y; Katsushima K; Ohka F; Natsume A; Shinjo K
Cancer Sci; 2014 Apr; 105(4):363-9. PubMed ID: 24843883
[TBL] [Abstract][Full Text] [Related]
6. Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas.
Wakimoto H; Tanaka S; Curry WT; Loebel F; Zhao D; Tateishi K; Chen J; Klofas LK; Lelic N; Kim JC; Dias-Santagata D; Ellisen LW; Borger DR; Fendt SM; Vander Heiden MG; Batchelor TT; Iafrate AJ; Cahill DP; Chi AS
Clin Cancer Res; 2014 Jun; 20(11):2898-909. PubMed ID: 24714777
[TBL] [Abstract][Full Text] [Related]
7. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
[TBL] [Abstract][Full Text] [Related]
8. IDH1 status is significantly different between high-grade thalamic and superficial gliomas.
Zuo M; Li M; Chen N; Yu T; Kong B; Liang R; Wang X; Mao Q; Liu Y
Cancer Biomark; 2017 Aug; 20(2):183-189. PubMed ID: 28869450
[TBL] [Abstract][Full Text] [Related]
9. DNA methylation, transcriptome and genetic copy number signatures of diffuse cerebral WHO grade II/III gliomas resolve cancer heterogeneity and development.
Binder H; Willscher E; Loeffler-Wirth H; Hopp L; Jones DTW; Pfister SM; Kreuz M; Gramatzki D; Fortenbacher E; Hentschel B; Tatagiba M; Herrlinger U; Vatter H; Matschke J; Westphal M; Krex D; Schackert G; Tonn JC; Schlegel U; Steiger HJ; Wick W; Weber RG; Weller M; Loeffler M
Acta Neuropathol Commun; 2019 Apr; 7(1):59. PubMed ID: 31023364
[TBL] [Abstract][Full Text] [Related]
10. Genetic and clinical characterization of B7-H3 (CD276) expression and epigenetic regulation in diffuse brain glioma.
Wang Z; Wang Z; Zhang C; Liu X; Li G; Liu S; Sun L; Liang J; Hu H; Liu Y; Zhang W; Jiang T
Cancer Sci; 2018 Sep; 109(9):2697-2705. PubMed ID: 30027617
[TBL] [Abstract][Full Text] [Related]
11. Impending Impact of Molecular Pathology on Classifying Adult Diffuse Gliomas.
Macaulay RJ
Cancer Control; 2015 Apr; 22(2):200-5. PubMed ID: 26068765
[TBL] [Abstract][Full Text] [Related]
12. Single-nucleus chromatin accessibility reveals intratumoral epigenetic heterogeneity in IDH1 mutant gliomas.
Al-Ali R; Bauer K; Park JW; Al Abdulla R; Fermi V; von Deimling A; Herold-Mende C; Mallm JP; Herrmann C; Wick W; Turcan Ş
Acta Neuropathol Commun; 2019 Dec; 7(1):201. PubMed ID: 31806013
[TBL] [Abstract][Full Text] [Related]
13. Paradoxical prognostic impact of TERT promoter mutations in gliomas depends on different histological and genetic backgrounds.
You H; Wu Y; Chang K; Shi X; Chen XD; Yan W; Li R
CNS Neurosci Ther; 2017 Oct; 23(10):790-797. PubMed ID: 28868656
[TBL] [Abstract][Full Text] [Related]
14. A machine learning analysis of a "normal-like" IDH-WT diffuse glioma transcriptomic subgroup associated with prolonged survival reveals novel immune and neurotransmitter-related actionable targets.
Nguyen HD; Allaire A; Diamandis P; Bisaillon M; Scott MS; Richer M
BMC Med; 2020 Oct; 18(1):280. PubMed ID: 33059718
[TBL] [Abstract][Full Text] [Related]
15. Isocitrate dehydrogenase status and molecular subclasses of glioma and glioblastoma.
Agnihotri S; Aldape KD; Zadeh G
Neurosurg Focus; 2014 Dec; 37(6):E13. PubMed ID: 25434382
[TBL] [Abstract][Full Text] [Related]
16. Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas.
Houdova Megova M; Drábek J; Dwight Z; Trojanec R; Koudeláková V; Vrbková J; Kalita O; Mlcochova S; Rabcanova M; Hajdúch M
Klin Onkol; 2017; 30(5):361-371. PubMed ID: 29031038
[TBL] [Abstract][Full Text] [Related]
17. Developmental origins and oncogenic pathways in malignant brain tumors.
Lu QR; Qian L; Zhou X
Wiley Interdiscip Rev Dev Biol; 2019 Jul; 8(4):e342. PubMed ID: 30945456
[TBL] [Abstract][Full Text] [Related]
18. Molecular subclassification of diffuse gliomas: seeing order in the chaos.
Huse JT; Phillips HS; Brennan CW
Glia; 2011 Aug; 59(8):1190-9. PubMed ID: 21446051
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic silencing of XAF1 in high-grade gliomas is associated with IDH1 status and improved clinical outcome.
Reich TR; Switzeny OJ; Renovanz M; Sommer C; Kaina B; Christmann M; Tomicic MT
Oncotarget; 2017 Feb; 8(9):15071-15084. PubMed ID: 28122345
[TBL] [Abstract][Full Text] [Related]
20. Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas.
Kim HS; Kwon MJ; Song JH; Kim ES; Kim HY; Min KW
Pathol Res Pract; 2018 Jun; 214(6):881-888. PubMed ID: 29650441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
